Cellular based immunotherapy for primary liver cancer

Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yuanyuan, Li, Yan, Feng, Jiao, Li, Jingjing, Ji, Jie, Wu, Liwei, Yu, Qiang, Dai, Weiqi, Wu, Jianye, Zhou, Yingqun, Guo, Chuanyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351445/
https://www.ncbi.nlm.nih.gov/pubmed/34372912
http://dx.doi.org/10.1186/s13046-021-02030-5
_version_ 1783735977553952768
author Zheng, Yuanyuan
Li, Yan
Feng, Jiao
Li, Jingjing
Ji, Jie
Wu, Liwei
Yu, Qiang
Dai, Weiqi
Wu, Jianye
Zhou, Yingqun
Guo, Chuanyong
author_facet Zheng, Yuanyuan
Li, Yan
Feng, Jiao
Li, Jingjing
Ji, Jie
Wu, Liwei
Yu, Qiang
Dai, Weiqi
Wu, Jianye
Zhou, Yingqun
Guo, Chuanyong
author_sort Zheng, Yuanyuan
collection PubMed
description Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cells play crucial roles in regulating tumor microenvironments and specifically recognizing tumor cells. Therefore, cellular based immunotherapy has its instinctive advantages in PLC therapy as a novel therapeutic strategy. From the active and passive immune perspectives, we introduced the cellular based immunotherapies for PLC in this review, covering both the lymphoid and myeloid cells. Then we briefly review the combined cellular immunotherapeutic approaches and the existing obstacles for PLC treatment.
format Online
Article
Text
id pubmed-8351445
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83514452021-08-10 Cellular based immunotherapy for primary liver cancer Zheng, Yuanyuan Li, Yan Feng, Jiao Li, Jingjing Ji, Jie Wu, Liwei Yu, Qiang Dai, Weiqi Wu, Jianye Zhou, Yingqun Guo, Chuanyong J Exp Clin Cancer Res Review Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cells play crucial roles in regulating tumor microenvironments and specifically recognizing tumor cells. Therefore, cellular based immunotherapy has its instinctive advantages in PLC therapy as a novel therapeutic strategy. From the active and passive immune perspectives, we introduced the cellular based immunotherapies for PLC in this review, covering both the lymphoid and myeloid cells. Then we briefly review the combined cellular immunotherapeutic approaches and the existing obstacles for PLC treatment. BioMed Central 2021-08-09 /pmc/articles/PMC8351445/ /pubmed/34372912 http://dx.doi.org/10.1186/s13046-021-02030-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zheng, Yuanyuan
Li, Yan
Feng, Jiao
Li, Jingjing
Ji, Jie
Wu, Liwei
Yu, Qiang
Dai, Weiqi
Wu, Jianye
Zhou, Yingqun
Guo, Chuanyong
Cellular based immunotherapy for primary liver cancer
title Cellular based immunotherapy for primary liver cancer
title_full Cellular based immunotherapy for primary liver cancer
title_fullStr Cellular based immunotherapy for primary liver cancer
title_full_unstemmed Cellular based immunotherapy for primary liver cancer
title_short Cellular based immunotherapy for primary liver cancer
title_sort cellular based immunotherapy for primary liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351445/
https://www.ncbi.nlm.nih.gov/pubmed/34372912
http://dx.doi.org/10.1186/s13046-021-02030-5
work_keys_str_mv AT zhengyuanyuan cellularbasedimmunotherapyforprimarylivercancer
AT liyan cellularbasedimmunotherapyforprimarylivercancer
AT fengjiao cellularbasedimmunotherapyforprimarylivercancer
AT lijingjing cellularbasedimmunotherapyforprimarylivercancer
AT jijie cellularbasedimmunotherapyforprimarylivercancer
AT wuliwei cellularbasedimmunotherapyforprimarylivercancer
AT yuqiang cellularbasedimmunotherapyforprimarylivercancer
AT daiweiqi cellularbasedimmunotherapyforprimarylivercancer
AT wujianye cellularbasedimmunotherapyforprimarylivercancer
AT zhouyingqun cellularbasedimmunotherapyforprimarylivercancer
AT guochuanyong cellularbasedimmunotherapyforprimarylivercancer

Ejemplares similares